# UK Viral Clearance Market > UK Viral Clearance Market Research Report By Method (Viral Removal Method, Viral Inactivation Method, Viral Detection Method), By Application (Blood and Blood Products, Recombinant Proteins, Cellular and amp Gene Therapy Products, Vaccines, Others) and By End-user (Pharmaceutical and Biotech Industry, Academic Research Institutes, CROs, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 22.0% - **2024:** $ 44 Million - **2025:** $ 53.68 Million - **2035:** $ 392.18 Million - **Key Players:** Sartorius (DE), Merck KGaA (DE), Thermo Fisher Scientific (US), Charles River Laboratories (US), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (GB), KBI Biopharma (US), WuXi AppTec (CN) **Report ID:** MRFR/HC/50367-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-viral-clearance-market-52125 --- ## Market Summary ## **UK Viral Clearance Market Overview** As per MRFR analysis, the UK Viral Clearance Market Size was estimated at 50.4 (USD Million) in 2023. The UK Viral Clearance Market Industry is expected to grow from 61.6(USD Million) in 2024 to 145 (USD Million) by 2035. The UK Viral Clearance Market CAGR (growth rate) is expected to be around 8.093% during the forecast period (2025 - 2035). ### **Key UK Viral Clearance Market Trends Highlighted** The growing demand for biopharmaceutical products that are both safe and effective is a significant market driver in the UK Viral Clearance Market. Regulators in the United Kingdom, including the Medicines and Healthcare Products Regulatory Agency (MHRA), prioritize stringent safety and efficacy standards that require comprehensive viral clearance processes in response to the expansion of the biotechnology sector and the development of biopharmaceuticals. Effective viral clearance technologies have also been necessitated by the increased awareness of infectious diseases, particularly in the aftermath of the COVID-19 pandemic.  Advancements in viral eradication methods, including the introduction of innovative technologies like single-use systems and enhanced filtration techniques, can be used to capitalize on opportunities in this market. The UK government's dedication to the development of healthcare infrastructure and the encouragement of biotech innovations facilitates the introduction of innovative solutions that address the evolving complexities of viral clearance by both new entrants and existing players. Furthermore, there are numerous prospects for expansion, as research institutions and companies that specialize in the development of innovative technologies establish partnerships. Recent trends in the United Kingdom suggest a trend toward the implementation of automation in viral clearance processes.  In addition to improving efficiency, this automation will also more effectively guarantee compliance with regulatory requirements. Furthermore, there is a growing emphasis on sustainability and the mitigation of the environmental impact of viral eradication systems, which has prompted companies to investigate eco-friendly alternatives.The demand for transparent and efficient viral clearance methodologies is further bolstered by the United Kingdom's emphasis on ethical practices in drug development, which will facilitate a more resilient market landscape in the future. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **UK Viral Clearance Market Drivers** Increasing Demand for Viral Clearance in Biopharmaceuticals The UK Viral Clearance Market Industry is experiencing significant growth due to the increasing demand for viral clearance in the biopharmaceutical sector. The Biopharmaceuticals Sector in the UK is projected to grow at a CAGR of 6.4%, driven by advances in biomanufacturing and a rising number of biopharmaceutical products coming to market. This growth is partly attributed to organizations such as the Association of the British Pharmaceutical Industry (ABPI) advocating for stringent safety standards to mitigate the risks associated with viral contamination.With over 100 biopharmaceutical manufacturers in the UK, as confirmed by the UK government statistics, the need for effective viral clearance processes is paramount, which is expected to propel the market towards greater innovations and investments in viral clearance methods. As the demand for biologics increases, the necessity for viral clearance becomes essential, paving the way for growth in the UK Viral Clearance Market Industry. Regulatory Support and Stringent Guidelines Regulatory frameworks in the UK have been evolving to place greater emphasis on patient safety and product efficacy, directly impacting the UK Viral Clearance Market Industry. The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has established stringent guidelines for the manufacturing of biopharmaceuticals, necessitating comprehensive viral clearance validation. The MHRA's emphasis on stringent safety protocols is evident, with 75% of pharmaceutical firms reporting that regulatory compliance has increased their investment in viral clearance measures. This focus on regulatory standards encourages innovation and adoption of advanced viral clearance technologies, translating into significant market growth opportunities. Rise in Vaccination and Gene Therapy Initiatives The ongoing rise in vaccination initiatives and gene therapy developments in the UK is significantly driving demand for viral clearance. The UK government has invested over 100 million in genomic medicine, aiming to improve treatments for genetic disorders. With the increase in the development of new vaccines, the need for robust viral clearance processes is paramount to ensure product safety. The recent push for COVID-19 vaccines, with many being developed locally, correlates with a heightened awareness of viral clearance measures. Additionally, the UK’s Vaccine Taskforce is focused on ensuring that vaccine development adheres to stringent safety protocols, further propelling the UK Viral Clearance Market Industry forward. ## **UK Viral Clearance Market Segment Insights** ### **Viral Clearance Market Method Insights** The UK Viral Clearance Market is gaining increasing prominence, driven by a growing focus on ensuring the safety and efficacy of biological products. The Method segment within this market encompasses various techniques crucial for mitigating viral risks, fundamentally contributing to public health, particularly in the biopharmaceutical and biotechnology sectors. Among these techniques, the Viral Removal Method is essential as it effectively separates viral contaminants from products, thereby ensuring high purity levels in vaccines and therapeutics. Additionally, the Viral Inactivation Method plays a critical role, especially in the processing of blood products and biologics, by neutralizing viral pathogens without compromising product integrity. This method's significance is heightened in light of regulatory mandates that require rigorous safety standards, making it an integral aspect of the overall viral clearance strategy.  Furthermore, the Viral Detection Method is pivotal in identifying viral presence at different stages of production, reflecting advancements in diagnostic technologies that improve detection sensitivity and specificity.Taken together, these methodologies dominate the viral clearance landscape and represent a robust framework for managing viral contamination risks. The interplay of these techniques under the auspices of a stringent regulatory environment shapes the UK Viral Clearance Market, pushing for continual innovation and adherence to best practices in quality control.  The increasing incidence of viral outbreaks and the concomitant rise in the demand for safe biological products further drive investment into method development. Collectively, the method segmentation of the UK Viral Clearance Market underlines the industry's commitment to safety, quality assurance, and continuous improvement in therapeutic developments. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **Viral Clearance Market Application Insights** The Application segment within the UK Viral Clearance Market plays a crucial role in ensuring the safety and efficacy of various therapeutic products. Blood and blood products represent a vital category due to their critical use in transfusions and treatment protocols, where stringent viral clearance is paramount to prevent transmission of infections. Recombinant proteins are also significant as they are widely used in biopharmaceuticals, necessitating robust viral clearance processes to uphold patient safety. Furthermore, Cellular and Gene Therapy Products are gaining importance in the UK market, driven by advanced treatment modalities that require comprehensive clearance solutions to mitigate viral risks. Vaccines are essential in bolstering public health, and their production involves rigorous viral clearance methodologies to ensure that these products are safe for mass immunization programs. Other applications contribute to the market by incorporating innovative technologies aimed at enhancing viral clearance protocols. Overall, the focus on these applications is driven by regulatory pressures and the increasing demand for safe biological products in the UK healthcare landscape. The growth in these areas highlights the need for continuous advancements in viral clearance technologies and processes within the industry. ### **Viral Clearance Market End-user Insights** The End-user segment of the UK Viral Clearance Market showcases a diverse landscape driven by various entities. The Pharmaceutical and Biotech Industry plays a crucial role, often leading in advancements and emphasizing strict compliance with regulatory mandates to ensure product safety, thus establishing a significant foothold in the market. Academic Research Institutes contribute by spearheading vital studies essential for innovative viral clearance techniques, fostering a collaborative environment to enhance industry standards. Contract Research Organizations (CROs) support the market by offering specialized services that streamline the viral clearance processes, addressing the growing demand for outsourcing in the industry. Other end-users encompass a range of entities, including emerging biopharmaceutical firms and diagnostic companies, expanding the scope and dynamics of the market. This diversity within the End-user segment not only underscores the vital contributions from each participant but also mirrors the increasing focus on regulatory compliance and innovative solutions within the UK Viral Clearance Market landscape, driving overall growth and development. As the market continues to evolve, each of these end-user categories will play an important role in shaping the future of viral clearance methodologies. ## **UK Viral Clearance Market Key Players and Competitive Insights** The UK Viral Clearance Market is a crucial segment within the biopharmaceutical industry, driven by the increasing demand for viral safety in therapeutic products and the rigorous regulations governing vaccine and biologics development. The competitive landscape is characterized by several key players, all striving to enhance their technical capabilities and provide innovative solutions that ensure product safety. Companies in this market engage in extensive research and development to introduce advanced technologies that can efficiently eliminate viral contaminants from biopharmaceuticals, thereby protecting patient safety. This market is not only shaped by product offerings but also influenced by strategic alliances, collaborations, and the ability to meet stringent regulatory requirements, ensuring a constantly evolving competitive environment. Sartorius has established a formidable presence in the UK Viral Clearance Market, renowned for its commitment to quality and innovative solutions tailored for biopharmaceutical applications. The company's strengths lie in its robust portfolio of advanced filtration and purification technologies that are vital in ensuring the viral safety of biologics. Sartorius invests heavily in research and development, allowing it to maintain a competitive edge by consistently introducing groundbreaking solutions that address the evolving needs of the market. Its reputation for quality and reliability is complemented by an extensive network of partnerships with industry stakeholders, further solidifying its position as a leader in the viral clearance domain within the UK. Eppendorf is another significant player in the UK Viral Clearance Market, recognized for its state-of-the-art products and services designed for life science research and bioprocessing. The company offers a range of solutions, including filtration systems, purification kits, and analytical instruments, all of which are critical for effective viral clearance in biopharmaceutical manufacturing. Eppendorf's strengths in research and development enable it to stay ahead of industry trends, while its strategic mergers and acquisitions enhance its technological capabilities and market reach. The company's commitment to sustainability and innovation has helped it secure a strong foothold in the UK market, thereby contributing significantly to the overall advancement of viral clearance methodologies in the region. By focusing on customer-centric solutions and operational excellence, Eppendorf continues to play a vital role in ensuring the safety and efficacy of therapeutic products in the UK. **Key Companies in the UK Viral Clearance Market Include** ## **UK Viral Clearance Market Industry Developments** The UK Viral Clearance Market has seen significant developments recently, particularly concerning several key players such as Sartorius, Eppendorf, and Merck Group. In October 2023, Sartorius announced an increase in their market share due to rising demand for biopharmaceutical products, which has led to a notable growth in their valuation. Eppendorf has also reported advancements in its viral clearance technologies that enhance safety in biologics production. In the realm of mergers and acquisitions, Charles River Laboratories completed the acquisition of a small biotech firm in September 2023 to bolster their offerings within the UK market, further consolidating their presence in the sector.  Pall Corporation and WuXi AppTec have been collaborating on various projects aimed at improving viral clearance processes, leading to innovations that address ongoing challenges in the market. The ongoing demand for vaccines and biologics, particularly in light of the recent COVID-19 pandemic, has certainly accelerated growth within this sector. Over the past few years, regulatory changes and technological advancements have driven the UK's viral clearance initiatives, establishing stringent safety standards and enhancing operational efficiencies for companies in this field. ## **UK Viral Clearance Market Segmentation Insights** ### **Viral Clearance Market Method****Outlook** ### **Viral Clearance Market Application****Outlook** ### **Viral Clearance Market End-user****Outlook** ## Market Drivers ### Stringent Regulatory Frameworks The viral clearance market is significantly influenced by the stringent regulatory frameworks established by health authorities in the UK. Regulatory bodies, such as the Medicines and Healthcare products Regulatory Agency (MHRA), enforce rigorous guidelines to ensure the safety of biopharmaceutical products. Compliance with these regulations is essential for market players, as failure to adhere can result in severe penalties or product recalls. The viral clearance market must continuously evolve to meet these regulatory demands, which may involve investing in new technologies and processes. As regulations become more complex, the market is expected to grow, with an emphasis on compliance-driven solutions. ### Increased Focus on Patient Safety The heightened focus on patient safety in the UK healthcare system is a significant driver for the viral clearance market. As healthcare providers and patients become more aware of the risks associated with viral contamination, the demand for effective viral clearance solutions is likely to rise. This trend is reflected in the growing investments in research and development aimed at improving viral clearance methodologies. The viral clearance market is expected to benefit from this shift, as companies prioritize the development of safer and more efficient viral clearance processes. This focus on safety may lead to a more competitive market landscape, with companies striving to offer superior solutions. ### Growing Investment in Biotechnology The growing investment in biotechnology within the UK is a key driver for the viral clearance market. As venture capital and government funding increase, biotechnology firms are expanding their research and development efforts, particularly in the area of viral clearance. This influx of capital is likely to lead to the development of novel viral clearance technologies and methodologies. The viral clearance market stands to benefit from this trend, as increased funding can facilitate the advancement of more effective and efficient solutions. As the biotechnology sector continues to thrive, the demand for robust viral clearance processes is expected to rise, further propelling market growth. ### Rising Demand for Biopharmaceuticals The increasing demand for biopharmaceuticals in the UK is a primary driver for the viral clearance market. As the biopharmaceutical sector expands, the need for effective viral clearance processes becomes critical to ensure product safety and efficacy. In 2025, the biopharmaceutical market in the UK is projected to reach approximately £30 billion, highlighting the necessity for robust viral clearance methods. This growth is likely to stimulate investments in advanced viral clearance technologies, thereby enhancing the overall market landscape. The viral clearance market must adapt to these demands by developing innovative solutions that meet regulatory standards and consumer expectations. ### Technological Innovations in Viral Clearance Technological innovations play a crucial role in shaping the viral clearance market. Advancements in filtration, chromatography, and inactivation technologies are enhancing the efficiency and effectiveness of viral clearance processes. In the UK, the adoption of these technologies is expected to increase, driven by the need for higher safety standards in biopharmaceutical production. The viral clearance market is likely to witness a surge in demand for innovative solutions that can provide faster and more reliable results. As companies invest in research and development, the market may experience significant growth, with new technologies emerging to address evolving challenges. ## Future Outlook The [Viral clearance market](https://www.marketresearchfuture.com/reports/viral-clearance-market-11268) is projected to grow at 22.0% CAGR from 2025 to 2035, driven by increasing demand for biopharmaceuticals and stringent regulatory requirements. **New opportunities:** - Development of advanced viral filtration technologies for biopharmaceuticals. - Expansion of contract manufacturing services for viral clearance processes. - Investment in automated viral testing systems to enhance efficiency. By 2035, the market is expected to achieve substantial growth, driven by innovation and regulatory compliance. ## Segment Insights ### By Method: Viral Removal Method (Largest) vs. Viral Inactivation Method (Fastest-Growing) The UK viral clearance market displays significant diversity among its method segments. The Viral Removal Method holds the largest share within this category, primarily due to its established efficacy and adoption across research and biopharmaceutical applications. In contrast, the Viral Inactivation Method, while smaller, shows rapid growth as emerging technologies enhance its reliability and safety, attracting interest for new product developments. Growth trends in this segment are largely driven by a rising demand for effective viral clearance solutions in therapeutic product manufacturing. Increased regulatory scrutiny on viral safety, coupled with the expansion of biologics and advanced therapies, propels investments in innovative inactivation techniques. The Viral Detection Method also plays an essential role, supporting both compliance and quality assurance needs, which collectively enhances the market's dynamics. Viral Removal Method (Dominant) vs. Viral Inactivation Method (Emerging) The Viral Removal Method is recognized for its significant presence and proven effectiveness in the UK viral clearance market, leveraging techniques such as filtration and adsorption to ensure high levels of purity in biological products. Companies typically prefer this method for its reliability, making it a staple in both development and manufacturing processes. On the other hand, the Viral Inactivation Method is emerging rapidly, incorporating innovative approaches like heat treatment and chemical agents to ensure robust viral safety. As the market shifts towards safer therapeutic approaches, this method is gaining traction, particularly in sectors focusing on patient safety and compliance with stringent regulations. ### By Application: Blood and Blood Products (Largest) vs. Vaccines (Fastest-Growing) Among the various segments within the UK viral clearance market, Blood and Blood Products holds the largest market share due to the critical demand for safety in transfusion-related therapies. Following closely are Recombinant Proteins, Cellular & Gene Therapy Products, and Vaccines, which showcase significant interest among stakeholders. The Others category also contributes to the overall market share but remains comparatively smaller, reflecting a diverse range of applications beyond the primary categories. Growth trends in the segment are driven by the increasing prevalence of viral infections and the rising demand for safer therapeutic options. Technological advancements in viral clearance methods are also a significant factor, making the process more efficient and reliable. The COVID-19 pandemic has further accelerated the focus on Vaccines, marking it as the fastest-growing segment as companies invest heavily in innovative solutions to combat viral threats. Blood and Blood Products (Dominant) vs. Vaccines (Emerging) Blood and Blood Products remain a dominant force in the UK viral clearance market owing to their essential role in healthcare, particularly in transfusion medicine. The rigorous regulatory requirements surrounding blood safety help maintain a solid market position. On the other hand, Vaccines represent an emerging segment that is rapidly gaining traction due to recent global health events. Advancements in vaccine development technologies, boosted by urgency from health crises, are propelling this segment's growth. Both segments cater to critical healthcare needs, yet their market dynamics and growth trajectories differ significantly, illustrating the evolving landscape of the UK viral clearance market. ### By End-user: Pharmaceutical and Biotech Industry (Largest) vs. CROs (Fastest-Growing) In the UK viral clearance market, the Pharmaceutical and Biotech Industry holds a substantial market share, dominating the segment landscape with its continuous demand for innovative viral clearance solutions. Meanwhile, Academic Research Institutes and CROs are also significant players, but they occupy relatively smaller portions of the market. The Others category encompasses various additional end-users, contributing to the overall segment distribution. The continuous expansion and need for therapeutics are driving this diverse market share allocation. The growth trends within the end-user segment are primarily driven by the increasing focus on drug development and the rising need for viral clearance in therapeutics. The Pharmaceutical and Biotech Industry is seeing sustained growth due to the burgeoning pipeline of biologics, while CROs are emerging as the fastest-growing segment as they provide specialized services catering to the needs of pharmaceutical clients. This trend showcases a shift where reliance on outsourced solutions for viral clearance is accelerating, which is indicative of broader changes in the drug development landscape. Pharmaceutical and Biotech Industry (Dominant) vs. CROs (Emerging) The Pharmaceutical and Biotech Industry is characterized by its strong presence in the UK viral clearance market, driven by a significant investment in research and development aimed at therapeutic innovations. This sector leverages advanced technologies to ensure compliance with stringent regulatory standards for safety and efficacy, thus solidifying its dominant market position. In contrast, CROs, while emerging, are becoming increasingly vital due to their ability to offer flexible and cost-effective solutions, attracting companies looking to streamline their drug development processes. As regulatory challenges continue to evolve, CROs are positioned to expand their services and expertise, making them essential partners for pharmaceutical firms seeking to navigate the complexities of viral clearance in an efficient manner. ## Competitive Benchmarking The viral clearance market is characterized by a dynamic competitive landscape, driven by increasing demand for biopharmaceuticals and stringent regulatory requirements. Key players such as Sartorius (DE), Merck KGaA (DE), and Thermo Fisher Scientific (US) are strategically positioned to leverage innovation and technological advancements. Sartorius (DE) focuses on enhancing its product portfolio through continuous R&D, while Merck KGaA (DE) emphasizes strategic partnerships to expand its market reach. Thermo Fisher Scientific (US) adopts a customer-centric approach, tailoring solutions to meet specific client needs, thereby shaping a competitive environment that prioritizes adaptability and responsiveness.In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. The market appears moderately fragmented, with a mix of established players and emerging firms. This structure allows for a diverse range of offerings, yet the collective influence of major companies like Lonza Group (CH) and Charles River Laboratories (US) is significant, as they set industry standards and drive innovation. In October Lonza Group (CH) announced a strategic collaboration with a leading biotech firm to enhance its viral clearance capabilities. This partnership is expected to bolster Lonza's position in the market by integrating advanced technologies that improve efficiency and efficacy in viral clearance processes. Such collaborations indicate a trend towards leveraging external expertise to accelerate innovation and meet evolving regulatory demands. In September Charles River Laboratories (US) launched a new suite of viral clearance services aimed at biopharmaceutical clients. This initiative reflects the company's commitment to expanding its service offerings and addressing the growing need for comprehensive viral safety solutions. By enhancing its capabilities, Charles River Laboratories (US) positions itself as a key player in ensuring the safety and efficacy of biopharmaceutical products. In August Merck KGaA (DE) unveiled a new viral clearance technology that utilizes advanced filtration methods. This innovation is poised to enhance the efficiency of viral removal processes, thereby reducing production costs for biopharmaceutical manufacturers. The introduction of such technologies underscores the importance of continuous innovation in maintaining competitive advantage within the market. As of November current trends in the viral clearance market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to tackle complex challenges. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability, as companies strive to meet the demands of a rapidly changing market. ## Recent News & Developments The UK Viral Clearance Market has seen significant developments recently, particularly concerning several key players such as Sartorius, Eppendorf, and Merck Group. In October 2023, Sartorius announced an increase in their market share due to rising demand for biopharmaceutical products, which has led to a notable growth in their valuation. Eppendorf has also reported advancements in its viral clearance technologies that enhance safety in biologics production. In the realm of mergers and acquisitions, Charles River Laboratories completed the acquisition of a small biotech firm in September 2023 to bolster their offerings within the UK market, further consolidating their presence in the sector.  Pall Corporation and WuXi AppTec have been collaborating on various projects aimed at improving viral clearance processes, leading to innovations that address ongoing challenges in the market. The ongoing demand for vaccines and biologics, particularly in light of the recent COVID-19 pandemic, has certainly accelerated growth within this sector. Over the past few years, regulatory changes and technological advancements have driven the UK's viral clearance initiatives, establishing stringent safety standards and enhancing operational efficiencies for companies in this field. ## Report Scope | MARKET SIZE 2024 | 44.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 53.68(USD Million) | | MARKET SIZE 2035 | 392.18(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 22.0% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Sartorius (DE), Merck KGaA (DE), Thermo Fisher Scientific (US), Charles River Laboratories (US), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (GB), KBI Biopharma (US), WuXi AppTec (CN) | | Segments Covered | Method, Application, End-user | | Key Market Opportunities | Advancements in filtration technologies enhance safety and efficacy in the viral clearance market. | | Key Market Dynamics | Regulatory changes drive innovation and competition in the viral clearance market, enhancing product efficacy and safety. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What is the current valuation of the UK viral clearance market?** A: The market valuation was $44.0 Million in 2024. **Q: What is the projected market size for the UK viral clearance market by 2035?** A: The market is expected to reach $392.18 Million by 2035. **Q: What is the expected CAGR for the UK viral clearance market during the forecast period 2025 - 2035?** A: The expected CAGR is 22.0% during the forecast period. **Q: Which companies are considered key players in the UK viral clearance market?** A: Key players include Sartorius, Merck KGaA, Thermo Fisher Scientific, and others. **Q: What are the main methods used in the UK viral clearance market?** A: The main methods include Viral Removal, Viral Inactivation, and Viral Detection. **Q: How much revenue did the Viral Inactivation Method generate in 2024?** A: The Viral Inactivation Method generated $180.0 Million in 2024. **Q: What applications are driving the UK viral clearance market?** A: Applications include Blood and Blood Products, Recombinant Proteins, and Vaccines. **Q: What was the revenue from Blood and Blood Products in 2024?** A: Blood and Blood Products generated $90.0 Million in 2024. **Q: Which end-users are contributing to the UK viral clearance market?** A: End-users include the Pharmaceutical and Biotech Industry, Academic Research Institutes, and CROs. **Q: What was the revenue generated by the Pharmaceutical and Biotech Industry in 2024?** A: The Pharmaceutical and Biotech Industry generated $176.09 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-viral-clearance-market-52125*